|
Report No. : |
356411 |
|
Report Date : |
24.12.2015 |
IDENTIFICATION DETAILS
|
Name : |
GUANGDONG SOUTH PHARMACEUTICAL FOREIGN TRADE CO., LTD. |
|
|
|
|
Registered Office : |
Room 1104-1105, 11/F Guangdong Holdings Tower No. 555 Dongfend Road,
Yuexiu District Guangzhou, Guangdong Province 510050 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2014 |
|
|
|
|
Date of Incorporation : |
26.04.1994 |
|
|
|
|
Com. Reg. No.: |
91440000190374694F |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Importing and exporting commodities and technology; medical
information consulting, and exhibition; wholesaling medicine, chemical raw material
medicine, chemical preparation, antibiotic raw material medicine, antibiotic
preparations, biochemical drugs, biological products, the second category of
psychotropic drugs, anabolic agents peptide hormones; selling medical
devices; wholesaling retailing pre packaged foods, and dairy products;
andselling cosmetics, grocery, clothing, shoes and hats; storage and logistic
service. |
|
|
|
|
No. of Employee : |
50 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHINA ECONOMIC OVERVIEW
Since the
late 1970s China has moved from a closed, centrally planned system to a more
market-oriented one that plays a major global role - in 2010 China became the world's
largest exporter. Reforms began with the phasing out of collectivized
agriculture, and expanded to include the gradual liberalization of prices,
fiscal decentralization, increased autonomy for state enterprises, growth of
the private sector, development of stock markets and a modern banking system,
and opening to foreign trade and investment. China has implemented reforms in a
gradualist fashion. In recent years, China has renewed its support for
state-owned enterprises in sectors considered important to "economic
security," explicitly looking to foster globally competitive industries.
The restructuring of the economy and resulting efficiency gains have
contributed to a more than tenfold increase in GDP since 1978. Measured on a
purchasing power parity (PPP) basis that adjusts for price differences, China
in 2014 stood as the largest economy in the world, surpassing the US for the
first time in modern history. Still, China's per capita income is below the
world average.
After
keeping its currency tightly linked to the US dollar for years, in July 2005
China moved to an exchange rate system that references a basket of currencies.
From mid-2005 to late 2008 cumulative appreciation of the renminbi against the
US dollar was more than 20%, but the exchange rate remained virtually pegged to
the dollar from the onset of the global financial crisis until June 2010, when
Beijing allowed resumption of a gradual appreciation. In 2014 the People’s Bank
of China (PBOC) doubled the daily trading band within which the RMB is
permitted to fluctuate.
The
Chinese government faces numerous economic challenges, including: (a) reducing
its high domestic savings rate and correspondingly low domestic consumption;
(b) facilitating higher-wage job opportunities for the aspiring middle class,
including rural migrants and increasing numbers of college graduates; (c)
reducing corruption and other economic crimes; and (d) containing environmental
damage and social strife related to the economy's rapid transformation.
Economic development has progressed further in coastal provinces than in the
interior, and by 2014 more than 274 million migrant workers and their
dependents had relocated to urban areas to find work. One consequence of
population control policy is that China is now one of the most rapidly aging
countries in the world. Deterioration in the environment - notably air
pollution, soil erosion, and the steady fall of the water table, especially in
the North - is another long-term problem. China continues to lose arable land because
of erosion and economic development. The Chinese government is seeking to add
energy production capacity from sources other than coal and oil, focusing on
nuclear and alternative energy development.
Several
factors are converging to slow China's growth, including debt overhang from its
credit-fueled stimulus program, industrial overcapacity, inefficient allocation
of capital by state-owned banks, and the slow recovery of China's trading
partners. The government's 12th Five-Year Plan, adopted in March 2011 and
reiterated at the Communist Party's "Third Plenum" meeting in
November 2013, emphasizes continued economic reforms and the need to increase
domestic consumption in order to make the economy less dependent in the future
on fixed investments, exports, and heavy industry. However, China has made only
marginal progress toward these rebalancing goals. The new government of
President XI Jinping has signaled a greater willingness to undertake reforms
that focus on China's long-term economic health, including giving the market a
more decisive role in allocating resources. In 2014 China agreed to begin
limiting carbon dioxide emissions by 2030. China also implemented several
economic reforms in 2014, including passing legislation to allow local
governments to issue bonds, opening several state-owned enterprises to further
private investment, loosening the one-child policy, passing harsher pollution
fines, and cutting administrative red tape.
|
Source
: CIA |
COMPANY NAME AND ADDRESS
GUANGDONG SOUTH PHARMACEUTICAL FOREIGN TRADE CO., LTD.
ROOM 1104-1105, 11/F GUANGDONG HOLDINGS TOWER
NO. 555 DONGFEND ROAD, YUEXIU DISTRICT
GUANGZHOU, GUANGDONG PROVINCE 510050 PR CHINA
TEL: 86 (0) 20-83858488
FAX: 86 (0) 20-28296866
EXECUTIVE SUMMARY
Date of Registration : APRIL 26, 1994
Unified social credit code : 91440000190374694F
LEGAL FORM : Limited Liability Company
REGISTERED CAPITAL : CNY 30,000,000
staff : 50
BUSINESS CATEGORY : TRADING
Revenue : CNY 2,122,320,000 (AS OF DEC. 31, 2014)
EQUITIES : CNY 208,140,000 (AS OF DEC. 31, 2014)
WEBSITE : www.sino-pharmgd.com
E-MAIL : N/A
PAYMENT : AVERAGE
MARKET CONDITION : competitive
FINANCIAL CONDITION : fairly stable
OPERATIONAL TREND : fairly
steady
GENERAL REPUTATION : average
EXCHANGE RATE : CNY 6.48 = USD
ADOPTED ABBREVIATIONS (AS FOLLOWS)
SC - Subject Company
(the company inquired by you)
N/A – Not available
CNY – China Yuan Ren
Min Bi
OPERATIONAL TREND
& GENERAL REPUTATION
This section aims at indicating the relative positions of SC in respect
of its operational trend & general reputation
Operational Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not known Not
yet be determined
Not yet be determined
LEGAL STATUS & HISTORY
SC was established
as a limited liabilities company of PRC with State Administration of Industry
& Commerce (SAIC) under Unified Social Credit Code: 91440000190374694F.
SC’s registered capital: CNY 30,000,000
SC’s paid-in capital: CNY 30,000,000
Registration Change Record:-
No significant changes of SC have been noted
in SAIC since its incorporation.
Current Co search indicates SC’s shareholders & chief executives are
as follows:-
|
Name of Shareholder (s) |
% of Shareholding |
|
China National Pharmaceutical Foreign
Trade Corporation |
51 |
|
Fu Yuequn |
15 |
|
Zhang Zhaotang |
12 |
|
Liao Zhi |
6 |
|
Other 8 individuals |
16 |
SC’s Chief Executives:-
|
Position |
Name |
|
Legal Representative, General Manager and
Director |
Fu Yuequn |
|
Chairman |
Yan Bing |
|
Director |
Zhang Zhaotang |
|
Wu Yu |
|
|
Sun Qin |
|
|
Supervisor |
Wang Ning |
RECENT DEVELOPMENT
No recent development was found during our checks at present.
SHAREHOLDER CHART & BACKGROUND
China National Pharmaceutical Foreign Trade
Corporation 51
Fu Yuequn 15
Zhang Zhaotang 12
Liao Zhi 6
Other 8 individuals 16
China National Pharmaceutical Foreign Trade
Corporation
-----------------------------------------------------------------------
Registration No.: 100000000000313
Web: www.sino-pharm.com
MANAGEMENT
Fu Yuequn, Legal Representative, General Manager and
Director
-----------------------------------------------------------------------------------------------
Ø
Gender: M
Ø Qualification:
University
Ø Working experience
(s):
At
present, working in SC as legal representative, general manager and director
Yan Bing, Chairman
------------------------------------
Ø
Gender: M
Ø Qualification:
University
Ø Working experience
(s):
At
present, working in SC as chairman
Director
-----------
Zhang
Zhaotang
Wu
Yu
Sun
Qin
Supervisor
--------------
Wang
Ning
BUSINESS OPERATION
SC’s registered business scope includes importing and exporting
commodities and technology; medical information consulting, and exhibition;
wholesaling medicine, chemical raw material medicine, chemical preparation,
antibiotic raw material medicine, antibiotic preparations, biochemical drugs,
biological products, the second category of psychotropic drugs, anabolic agents
peptide hormones; selling medical devices; wholesaling retailing pre packaged
foods, and dairy products; andselling cosmetics, grocery, clothing, shoes and
hats; storage and logistic service.
SC is mainly
engaged in selling medicines and medical devices.
SC’s products
mainly include:
Injection
Tablet
Capsule
Granule
Pill
Oral Solution
SC sources the products 100% from domestic market. SC sells 30% of its products in domestic market, and 70% to overseas market.
The buying terms
of SC include Check, T/T and Credit of 30-60 days. The payment terms of SC
includes T/T, L/C and Credit of 30-60 days.
Staff & Office:
--------------------------
SC is known
to have approx. 50 staff at
present.
SC rents an area
as its operating office, but the detailed information is unknown.
RELATED COMPANY
SC
is not known to have any subsidiary at present.
PAYMENT
Overall payment appraisal:
( ) Excellent ( ) Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment experience (through current enquiry with SC's
suppliers), our delinquent payment and our debt collection record concerning
SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent payment record: None in our
database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
BANKING
The bank
information of SC is not filed in local SAIC.
FINANCIALS
Financial Summary
|
Unit: CNY’000 |
As
of Dec. 31, 2014 |
|
Total assets |
930,610 |
|
|
------------- |
|
Total
liabilities |
722,470 |
|
Equities |
208,140 |
|
|
------------- |
|
Revenue |
2,122,320 |
|
Profits |
36,330 |
Important Ratios
=============
|
|
As
of Dec. 31, 2014 |
|
*Liabilities
to assets |
0.78 |
|
*Net profit margin
(%) |
1.71 |
|
*Return on
total assets (%) |
3.90 |
|
*
Revenue/Total assets |
2.28 |
FINANCIAL COMMENTS
PROFITABILITY:
AVERAGE
l The revenue of SC
appears fairly good in its line.
l SC’s net profit
margin is average.
l SC’s return on total
assets is average.
LIQUIDITY: AVERAGE
l
SC’s revenue is in an average level, comparing with
the size of its total assets.
LEVERAGE: AVERAGE
l
The debt ratio of SC is average.
l
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fairly Stable.
CONCLUSIONS
SC is considered medium-sized in its line with fairly stable financial
conditions. Taking into consideration of SC’s general performance, reputation
as well as market conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.20 |
|
|
1 |
Rs.98.30 |
|
Euro |
1 |
Rs.72.41 |
|
CNY |
1 |
Rs.10.19 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.